[go: up one dir, main page]

TR199903057T2 - Diabetin tiazolidinedion ve metformin ile tedavisi. - Google Patents

Diabetin tiazolidinedion ve metformin ile tedavisi.

Info

Publication number
TR199903057T2
TR199903057T2 TR1999/03057T TR9903057T TR199903057T2 TR 199903057 T2 TR199903057 T2 TR 199903057T2 TR 1999/03057 T TR1999/03057 T TR 1999/03057T TR 9903057 T TR9903057 T TR 9903057T TR 199903057 T2 TR199903057 T2 TR 199903057T2
Authority
TR
Turkey
Prior art keywords
treatment
diabetes
thiazolidinedione
metformin
diabetes mellitus
Prior art date
Application number
TR1999/03057T
Other languages
English (en)
Inventor
Alistair Smith Stephen
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199903057(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of TR199903057T2 publication Critical patent/TR199903057T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Buna ihtiyaç duyan bir memeliye bir insülin senzitizörünün ve bir biguanid antihiperglisaemik maddesinin farmasötik olarak kabul edilebilir, toksik olmayan ve etkili bir miktarinin uygulanmasini kapsayan, bir memelide diabet mellitus ile ilintili kosullarin ve diabet mellitusun tedavisi için bir metod ve insülin senzitizörü ile bir biguanid antihiperglisaemik madde içeren bir farmasötik terkip.
TR1999/03057T 1997-06-18 1998-06-15 Diabetin tiazolidinedion ve metformin ile tedavisi. TR199903057T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
TR199903057T2 true TR199903057T2 (tr) 2000-04-21

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03057T TR199903057T2 (tr) 1997-06-18 1998-06-15 Diabetin tiazolidinedion ve metformin ile tedavisi.

Country Status (38)

Country Link
US (3) US20060100247A1 (tr)
EP (2) EP1787646A3 (tr)
JP (1) JP2002504137A (tr)
KR (2) KR100666591B1 (tr)
CN (2) CN1114404C (tr)
AP (1) AP1279A (tr)
AR (2) AR012995A1 (tr)
AT (1) ATE355840T1 (tr)
AU (1) AU8539398A (tr)
BG (2) BG109398A (tr)
BR (1) BR9810172A (tr)
CA (1) CA2294582C (tr)
CY (2) CY1107643T1 (tr)
CZ (1) CZ298469B6 (tr)
DE (2) DE69837261T2 (tr)
DK (1) DK0996444T3 (tr)
DZ (1) DZ2520A1 (tr)
EA (1) EA003144B1 (tr)
ES (1) ES2284212T3 (tr)
ID (1) ID23372A (tr)
IL (3) IL133142A0 (tr)
IN (1) IN189722B (tr)
LU (1) LU91356I2 (tr)
MA (1) MA26512A1 (tr)
MY (1) MY129897A (tr)
NL (1) NL300288I2 (tr)
NO (4) NO324993B1 (tr)
NZ (1) NZ501260A (tr)
OA (1) OA11516A (tr)
PE (1) PE83199A1 (tr)
PL (2) PL195140B1 (tr)
PT (1) PT996444E (tr)
SI (1) SI0996444T1 (tr)
SK (1) SK286029B6 (tr)
TR (1) TR199903057T2 (tr)
TW (1) TW565449B (tr)
UY (1) UY25049A1 (tr)
WO (1) WO1998057634A1 (tr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW474809B (en) * 1995-07-03 2002-02-01 Sankyo Co A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP0974356B1 (en) * 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
AU3960400A (en) * 1999-03-05 2000-09-28 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP5183844B2 (ja) 1999-11-03 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー 糖尿病の治療方法
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
EP1231917A2 (en) * 1999-11-16 2002-08-21 Smithkline Beecham Plc Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
DE60129425T2 (de) * 2000-05-01 2008-04-17 Aeropharm Technology LLC, Dover Kernformulierung
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
BRPI0206432A2 (pt) 2001-01-12 2016-10-25 Sun Pharmaceutical Ind Ltd métodos para administrar dois ou mais agentes terapêuticos ativos e para tratar diabetes melito ou sintomas associados com diabetes melito em um humano e sistema de liberação espaçada de medicamento
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
KR101363679B1 (ko) * 2002-09-20 2014-02-14 안드렉스 랩스 엘엘씨 약제학적 정제
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
WO2004067001A1 (ja) 2003-01-29 2004-08-12 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US8263121B2 (en) 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
WO2006011397A1 (ja) * 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
WO2006086727A2 (en) * 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US20090137626A1 (en) * 2005-07-12 2009-05-28 Akira Okuno Pharmaceutical Composition Containing PPARgamma Agonist
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
JP2012503595A (ja) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
SI2661266T1 (sl) 2011-01-07 2021-01-29 Anji Pharma (Us) Llc Terapije, na osnovi kemosenzoričnih receptorskih ligandov
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
BR112014016810A8 (pt) 2012-01-06 2017-07-04 Elcelyx Therapeutics Inc composições e métodos para tratamento de distúrbios metabólicos
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
DE69822505T2 (de) * 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. Neue metformin-salze und verfahren
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
AU8539398A (en) 1999-01-04
CZ298469B6 (cs) 2007-10-10
ES2284212T3 (es) 2007-11-01
IL173650A0 (en) 2006-07-05
CN1260716A (zh) 2000-07-19
PL337362A1 (en) 2000-08-14
WO1998057634A1 (en) 1998-12-23
NO996266D0 (no) 1999-12-17
AP9901719A0 (en) 1999-12-31
BG104060A (en) 2000-10-31
DK0996444T3 (da) 2007-07-02
NZ501260A (en) 2002-09-27
KR20010013844A (ko) 2001-02-26
CN1114404C (zh) 2003-07-16
NL300288I1 (nl) 2007-11-01
AR012995A1 (es) 2000-11-22
EP1787646A3 (en) 2007-10-03
IL133142A (en) 2006-06-11
ATE355840T1 (de) 2007-03-15
NO2008003I2 (no) 2010-06-28
KR20060105005A (ko) 2006-10-09
NO324993B1 (no) 2008-01-14
UY25049A1 (es) 2000-09-29
CY1107643T1 (el) 2012-01-25
US20060100247A1 (en) 2006-05-11
IN189722B (tr) 2003-04-19
US20080090881A1 (en) 2008-04-17
PL195140B1 (pl) 2007-08-31
CA2294582A1 (en) 1998-12-23
CN1429551A (zh) 2003-07-16
NL300288I2 (nl) 2009-06-02
EP0996444A1 (en) 2000-05-03
SI0996444T1 (sl) 2007-08-31
JP2002504137A (ja) 2002-02-05
CZ9904578A3 (en) 2001-06-13
DE69837261D1 (de) 2007-04-19
EA003144B1 (ru) 2003-02-27
BG64818B1 (bg) 2006-05-31
SK286029B6 (sk) 2008-01-07
NO996266L (no) 1999-12-17
EA200000041A1 (ru) 2000-08-28
PL195136B1 (pl) 2007-08-31
SK179299A3 (en) 2000-11-07
OA11516A (en) 2004-02-04
US20070004780A1 (en) 2007-01-04
CY2007018I1 (el) 2012-01-25
MA26512A1 (fr) 2004-12-20
BR9810172A (pt) 2000-08-08
NO2008003I1 (no) 2008-04-21
IL133142A0 (en) 2001-03-19
PT996444E (pt) 2007-06-08
DE122007000054I1 (de) 2007-12-13
DZ2520A1 (fr) 2003-02-01
TW565449B (en) 2003-12-11
EP0996444B1 (en) 2007-03-07
LU91356I2 (fr) 2008-01-29
EP1787646A2 (en) 2007-05-23
ID23372A (id) 2000-04-20
NO326958B1 (no) 2009-03-23
DE69837261T2 (de) 2007-11-08
PE83199A1 (es) 1999-10-22
HK1028193A1 (en) 2001-02-09
NO20090846L (no) 1999-12-17
NO20063000L (no) 1999-12-17
AR012998A1 (es) 2000-11-22
AP1279A (en) 2004-05-20
KR100666591B1 (ko) 2007-01-11
MY129897A (en) 2007-05-31
CN1230171C (zh) 2005-12-07
BG109398A (bg) 2006-05-31
CA2294582C (en) 2008-02-12

Similar Documents

Publication Publication Date Title
TR199903057T2 (tr) Diabetin tiazolidinedion ve metformin ile tedavisi.
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
TR199903095T2 (tr) Diabetin roziglitazon ve insülin ile tedavisi.
TR199903072T2 (tr) Diabetin tiazolidinedion ve alfa-glukosidaz ile tedavisi.
TR200101336T2 (tr) Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
TR199903096T2 (tr) Diabetin tiazolidinedion ve sülfonilüre ile tedavisi.
BR9810292A (pt) Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase
ECSP982591A (es) Nuevo metodo de tratamiento iv
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı
ECSP982541A (es) Nuevo metodo de tratamiento ii
HUP0002668A2 (hu) Diabetes kezelésére dioxo-tiazolidinnel és metforminnal
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982542A (es) Nuevo metodo de tratamiento iii